1. Pink Sheet
  2. >>Biosimilars & Generics
  3. >>Biosimilars

First Biosimilar MabThera One Step Away from EU Approval; Pegfilgrastim Filings Withdrawn

 
• By Ian Schofield

The CHMP has granted a positive opinion to Celltrion’s Truxima, the first biosimilar version of Roche’s cancer treatment, MabThera, but has announced the withdrawal of two pegfilgrastim products.

Thumbs up
The CHMP has OKd the first EU biosimilar version of MabThera

If the European Commission follows the recommendation of the European Medicines Agency and approves Celltrion’s Truxima (rituximab), the product will become the first biosimilar version of Roche’s cancer drug MabThera to reach the EU market. It’s good news for Celltrion, but that’s not the case for Gedeon Richter, whose approval applications for Cavoley and Efgratin – biosimilar versions of Amgen’s Neulasta (pegfilgrastim) – have been withdrawn.

Truxima has received a positive opinion from the EMA’s scientific committee, the CHMP, for the treatment of non-Hodgkin’s...

Welcome to Pink Sheet

Create an account to read this article

Already a subscriber?

More from Biosimilars

Off-Patent Drugs Get UK Spotlight, But Picture Is Still ‘Nuanced’

 
• By Urtė Fultinavičiūtė

The importance of generic and biosimilar medicines is being recognized by the UK government for the first time. However, Mark Samuels, CEO of Medicines UK, the trade body representing the off-patent industry, says companies are still face multiple hurdles in the market.

US FDA Skips User Fee Increase For More Staff Amid Exodus, Hiring Difficulties

 
• By Derrick Gingery

A calculation used to determine whether the FDA has the staff to handle its workload also was not included in the description of prescription drug user fee calculations.

EU Biosimilar Filings, Opinions And Approvals

 
• By Neena Brizmohun

A list of EU biosimilar filings, CHMP opinions and EU marketing authorizations, including details of the biosimilar company, the brand name/INN, indication(s), the reference product/company, and the date and type of event.

EMA Backs Gilead’s Yeytuo And 13 Other Drugs For EU Approval But Rejects Three

 
• By Eliza Slawther and Neena Brizmohun

The European Medicines Agency’s human medicines committee, the CHMP, has recommended 14 new medicines for pan-EU approval this month, including five orphan medicines.

More from Biosimilars & Generics

US FDA Skips User Fee Increase For More Staff Amid Exodus, Hiring Difficulties

 
• By Derrick Gingery

A calculation used to determine whether the FDA has the staff to handle its workload also was not included in the description of prescription drug user fee calculations.

EU Biosimilar Filings, Opinions And Approvals

 
• By Neena Brizmohun

A list of EU biosimilar filings, CHMP opinions and EU marketing authorizations, including details of the biosimilar company, the brand name/INN, indication(s), the reference product/company, and the date and type of event.

Court Allows MSN Marketing Of Entresto Generic, But More Legal Issues Pending

 
• By Dean Rudge

Novartis failed to stop MSN from launching a generic Entresto and saw an earlier temporary ban lifted, potentially opening the market to competition before a final decision on a US patent dispute.